MARKET

MESO

MESO

Mesoblast
NASDAQ
16.88
-0.03
-0.18%
After Hours: 16.65 -0.23 -1.36% 19:37 02/20 EST
OPEN
16.89
PREV CLOSE
16.91
HIGH
16.98
LOW
16.70
VOLUME
168.43K
TURNOVER
--
52 WEEK HIGH
21.50
52 WEEK LOW
9.61
MARKET CAP
2.18B
P/E (TTM)
-19.9598
1D
5D
1M
3M
1Y
5Y
1D
Mesoblast Limited to Host Half-Year Financial Results Webcast
Reuters · 1d ago
Mesoblast Financial Results and Corporate Update Webcast
Barchart · 1d ago
Weekly Report: what happened at MESO last week (0209-0213)?
Weekly Report · 5d ago
Mesoblast Touts High Survival Rates For FDA-Approved Cell Therapy
Benzinga · 02/12 13:11
Mesoblast Touts Ryoncil Survival Data, Prepares Adult SR-aGvHD Pivotal Trial
TipRanks · 02/12 11:39
Mesoblast Reports High Survival With Ryoncil in SR-aGvHD and Plans Adult Pivotal Trial
Reuters · 02/11 23:28
High Survival Rates With Ryoncil® in EIND Program Emphasize Importance of Earlier Use in Both Children and Adults With SR-aGvHD
Barchart · 02/11 17:27
Mesoblast: Real-World Data Validates The Bull Case For Ryoncil
Seeking Alpha · 02/11 10:59
More
About MESO
Mesoblast Limited is an Australia-based company. The Company is engaged in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The Company has developing a range of late-stage product candidates, derived from its first and second generation proprietary mesenchymal lineage cell therapy technology platforms therapies for distinct indications. The Company’s Ryoncil (remestemcel-L-rknd) is an allogeneic bone marrow-derived mesenchymal stromal cell (MSC) therapy. Its other product candidate is Revascor (rexlemestrocel-L). Rexlemestrocel-L is second generation mesenchymal lineage precursor cell product platform and is in late-stage development for treatment of: chronic heart failure (chf) and chronic low back pain (clbp) due to degenerative disc disease. The two products have been commercialized in Japan and Europe by the Company's licensees.

Webull offers Mesoblast Ltd (ADR) stock information, including NASDAQ: MESO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MESO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading MESO stock methods without spending real money on the virtual paper trading platform.